Catalyst

Slingshot members are tracking this event:

Pfizer (PFE) Announces Phase 3 REFLECTIONS B537-02 Data Evaluating Remicade Biosimilar in Rheumatoid Arthritis

Source Link:
http://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_reflections_b537_02_study_for_pf_06438179_infliximab_pfizer_a_potential_biosimilar_to_remicade_infliximab

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
PFE
100%
NVS
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Sep 16, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Reflections B537-02, Remicade Biosimilar, Rheumatoid Arthritis
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.